Association of Multidrug-Resistant Tuberculosis (MDR-TB) Patients on Profile of Liver and Kidney Function
Abstract
Full Text:
PDFReferences
Stacey SL. Pulmonary tuberculosis: Improving diagnosis and management. JAAPA. 2016;29(2): 20-5.
Zaman K. Tuberculosis: a global health problem. J Health Popul Nutr. 2010;28(2): 111-113.
Giovanni D, Michela S, Giovanni F. The biology of mycobacterium tuberculosis infection. Mediterr J Hematol Infect Dis. 2013;5(1): e2013070.
World Health Organization. Global Tuberculosis Report. Geneva: World Health Organization; 2018.
R Lia K, Tryna T, Edward M, Virasakdi C. Predictors of multidrug resistance among pulmonary tuberculosis patients in a tertiary hospital in North Sumatera, Indonesia. Bali Med J. 2018;7(1): 68-73.
United States Agency International Development (USAID). Indonesia Tuberculosis Roadmap Overview, Fiscal Year 2021. Washington, D.C.: USAID; 2020.
Garza AZ, Park SB, Kocz R. Drug Elimination. 2020. URL: https://www.ncbi.nlm.nih.gov/books/NBK547662/. Accessed December 4, 2020.
Kalra A, Yetiskul E, Wehrle CJ, et al. Physiology, Liver. 2020. URL: https://www.ncbi.nlm.nih.gov/books/NBK535438/. Accessed May 24, 2020.
Ogobuiro I, Tuma F. Physiology, Renal. 2020. URL: https://www.ncbi.nlm.nih.gov/books/NBK538339/. Accessed August 29, 2020.
Kementerian Kesehatan RI. Peraturan Menteri Kesehatan Republik Indonesia No. 25 Tahun 2016 tentang Rencana Aksi Nasional Kesehatan Lanjut Usia Tahun 2016-2019. Jakarta: Kementerian Kesehatan RI; 2016.
Horton KC, MacPherson P, Houben RM, White RG, Corbett EL. Sex differences in tuberculosis burden and notifications in low- and middle-income countries: a systematic review and meta-analysis. PLoS Med. 2016;13(9): e1002119.
Hof S, Najlis CA, Bloss E, Straetemans M. A systematic review on the role of gender in tuberculosis control. 2010. URL: https://www.kncvtbc.org/uploaded/2015/09/Role_of_Gender_in_TB_Control.pdf. Accessed December 27, 2020.
Pradipta IS, Forsman LD, Bruchfeld J, Hak E, Alffenaar JW. Risk factors of multidrug-resistant tuberculosis: a global systematic review and meta-analysis. J Infect. 2018;77(6): 469-478.
Liguori I, Russo G, Curcio F, et al. Oxidative stress, aging, and diseases. Clin Interv Aging. 2018;13: 757-772.
Sapriadi S, Syahridha. Factor related to anti-tuberculosis drug resistency on pulmonary tuberculosis patients in labuang baji hospital Makassar. Indonesian Journal of Tropical and Infectious Disease. 2018;7(2): 40-4.
Alhawaris, Tabri NA. Risiko infeksi mycobacterium tuberculosis pada orang yang tinggal serumah dengan penderita tuberculosis di Makassar. Jurnal Kedokteran Mulawarman. 2020;7(1): 11-9.
Kementerian Kesehatan RI. Petunjuk teknis manajemen terpadu pengendalian resistan obat. Jakarta: Kementerian Kesehatan RI; 2014.
Torrico MM, Luna JC, Migliori GB, et al. Diabetes is associated with severe adverse events in multidrug-resistant tuberculosis. Arch Bronconeumol. 2017;53(5): 245-250.
Curry International Tuberculosis Center and California Department of Public Health. Drug-resistant tuberculosis: a survival guide for clinicians, third edition. San Fransisco: UCF; 2016.
Keshavjee S, Gelmanova IY, Shin SS, et al. Hepatotoxicity during treatment for multidrug-resistant tuberculosis: occurrence, management and outcome. Int J Tuberc Lung Dis. 2012;16(5): 596–603.
Verdiansah. Pemeriksaan fungsi ginjal. Cermin Dunia Kedokteran. 2016;43(2): 148–54.
Gounden V, Bhatt H, Jialal I. Renal Function Tests. 2020. URL: https://www.ncbi.nlm.nih.gov/books/NBK507821/. Accessed July 20, 2020.
Arnold A, Cooke GS, Kon OM, et al. Adverse effects and choice between the injectable agents amikacin and capreomycin in multidrug-resistant tuberculosis. Antimicrobial Agents Chemotherapy. 2017;61(9): e02586-16.
Seung KJ, Keshavjee S, Rich ML. Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Cold Spring Harb Perspect Med. 2015;5(9): a017863.
Reviono, Kusnanto P, Eko V, et al. Multidrug Resistant Tuberculosis (MDR-TB): Tinjauan Epidemiologi dan Faktor Risiko Efek Samping Obat Anti Tuberkulosis. MKB. 2014;26(4): 191-4.
Gezahegn, LK, Argaw, E, Assefa, B, et al. Magnitude, outcome, and associated factors of anti-tuberculosis drug-induced hepatitis among tuberculosis patients in a tertiary hospital in North Ethiopia: A cross-sectional study. PLoS ONE. 2020;15(11): 6-10.
Shamaei, M, Mirsaeidi, M, Baghaei, P, et al. Recurrent drug-induced hepatitis in tuberculosis-comparison of two drug regimen. Am J Ther. 2017;24(2): 2-5.
Saito, N, Yoshii, Y, Kaneko, Y, et al. Impact of renal function-based anti-tuberculosis drug dosage adjustment on efficacy and safety outcomes in pulmonary tuberculosis complicated with chronic kidney disease. BMC Infect Dis. 2019;19(374): 4-5.
DOI: http://dx.doi.org/10.30872/j.kes.pasmi.kal.v5i2.9640
Refbacks
- There are currently no refbacks.
Indexing by :